Overview
An 11-item clinician-administered cognitive battery developed specifically as an outcome measure for Alzheimer's disease clinical trials.
Use cases
Primary cognitive endpoint in Alzheimer's registration trials.
Assessment intelligence
- Score range
- 0 – 70
- Direction
- Higher = worse
- Scoring method
- Sum
- Time to score
- ~45 min
Subscales
- ADAS-Cog 11 total0-70
11-item cognitive subscale
Cutoff thresholds & interpretation
| Severity | Threshold | Interpretation |
|---|---|---|
| Trial-relevant change | ≥4 points | Clinically meaningful change in mild-to-moderate Alzheimer's trials |
Standard primary cognitive endpoint in Alzheimer's disease trials.
Editorial notes
Decades of regulatory use; ADAS-Cog13 extends sensitivity to earlier disease.
Available languages
Validation studies (2)
- A new rating scale for Alzheimer's diseaseRosen WG, Mohs RC, Davis KL. · American Journal of Psychiatry · 1984DOI: 10.1176/ajp.141.11.1356
- ADAS-Cog13 in early AD trial endpointsMohs RC, Knopman D, et al. · Alzheimer Disease and Associated Disorders · 1997DOI: 10.1097/00002093-199700112-00004
Related assessments
MMSE
Mini-Mental State Examination
Brief cognitive screen for dementia.
MoCAMontreal Cognitive Assessment
Cognitive screen with strong MCI sensitivity.
ACE-IIIAddenbrooke's Cognitive Examination III
Multi-domain cognitive screen with subtype sensitivity.
CDRClinical Dementia Rating
Gold-standard dementia staging instrument.